Austin-based biotechnology company XBiotech USA has received Fast Track status from the FDA for Xilonix, a therapeutic antibody that combats cachexia -- a condition found among patients with chronic inflammatory conditions. XBiotech will begin a trial to evaluate the efficacy of Xilonix in patients with advanced colorectal cancer and wasting syndrome.